Merck and Integra battle on

Integra v. Merck: Limiting the Scope of the 271(e)(1) Exception to Patent Infringement

Rofecoxib, Merck, and the FDA.

The new england journal of medicine 2875 correspondence Rofecoxib, Merck, and the FDA to the editor: Merck has been proactive and conscientious in evaluating the cardiovascular profile of rofecoxib (Vioxx); Dr. Topol's remarks to the contrary in his Perspective article (Oct. 21 issue) 1 are false. First, his description of the time line obfus-cates the facts. The Food and Drug Administration (F...

Merck Animal Health

Lancaster R.T., Foxcroft, G.R., Boland, M.R, Edwards, S. and Gordon, I., 1985. Fertility of sows treated with exogenous estradiol and/or gonadotropins to control postweaning estrus. Anim. Reprod. Sci., 8:365-373 In the first of two experiments 28 multiparous sows were allocated to one of the following treatments two days after weaning at approximately 35 days postpartum: (1) untreated; (2) i.m....

Analysis of lidocaine on the COBAS INTEGRA.

A new fluorescence polarization (FP) immunoassay was developed for the COBAS INTEGRA to quantitate lidocaine in serum and sodium heparin derived plasma. The COBAS INTEGRA, a random and continuous access clinical analyzer, performs the new lidocaine assay at a throughput of 300 tests per hour. Comparison studies with the Abbott TDx Lidocaine assay yielded a correlation coefficient of 0.99 and a ...

ATS Merck CME Newsletter

Charles M. Balch, MD, Professor of Surgery, Oncology and Dermatology, Johns Hopkins Medicine, Baltimore, reviewed the current version of the melanoma staging as well as new data on staging and prognosis contained in the 2008 version of the American Joint Committee on Cancer (AJCC) Melanoma Staging Schema. The final version of the melanoma staging criteria are embargoed until May 2009 and implem...